Other compounds

LGD-4033: molecular data, studies & sources

LGD-4033 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-01 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular record not yet resolved

A sufficiently specific molecular record was not resolved for this name. Formula, molecular weight and structure are withheld until the exact sequence, salt or preparation can be verified.

MF: not assigned · MW: not assigned · Structure: not assigned

Registered clinical trials

Studies registered on ClinicalTrials.gov that list LGD-4033 as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

1 registered study matched.

Study	Phase · status	Conditions	Sponsor · size
A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip FractureNCT02578095 · start 2015-10-30 · primary completion 2017-11-15	Phase 2Completed	Hip Fractures	Viking Therapeutics, Inc.108 participants

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

Human study · PubMed trial index
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.
Basaria S, Collins L, Dillon EL et al. · The journals of gerontology. Series A, Biological sciences and medical sciences · 2012
PMID 22459616 · DOI: 10.1093/gerona/gls078

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Preclinical / laboratory research
Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model.
Roch PJ, Henkies D, Carstens JC et al. · Frontiers in endocrinology · 2020
PMID 33042018 · DOI: 10.3389/fendo.2020.556581
Research publication · design requires review
Variation of Sequential Ligandrol (LGD-4033) Metabolite Levels in Routine Anti-Doping Urine Samples Detected with or without Other Xenobiotics.
Kwiatkowska D, Wicka M, Grucza K et al. · Molecules (Basel, Switzerland) · 2023
PMID 37764261 · DOI: 10.3390/molecules28186486
Case report
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.
Cardaci TD, Machek SB, Wilburn DT et al. · Experimental physiology · 2022
PMID 36303408 · DOI: 10.1113/EP090741
Research publication · design requires review
Human in vivo metabolism study of LGD-4033.
Fragkaki AG, Sakellariou P, Kiousi P et al. · Drug testing and analysis · 2018
PMID 30255601 · DOI: 10.1002/dta.2512
Research publication · design requires review
Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis.
Hoffmann DB, Derout C, Müller-Reiter M et al. · Journal of bone and mineral metabolism · 2023
PMID 37407738 · DOI: 10.1007/s00774-023-01453-8
Preclinical / laboratory research
Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration.
Sugumar D, Ghosh R, Rymbai E et al. · Assay and drug development technologies · 2024
PMID 39501873 · DOI: 10.1089/adt.2024.029
Research publication · design requires review
Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes.
Wagener F, Guddat S, Görgens C et al. · Analytical and bioanalytical chemistry · 2021
PMID 34734312 · DOI: 10.1007/s00216-021-03740-7

LGD-4033 supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.